ERBB2 and non-small cell lung carcinoma: It has been found that regardless of the type of EGFR-TKIs resistance mechanisms, such as EGFR T790M mutation, MET amplification, and HER2 amplification, HER3 amplification is observed in EGFR-mutated NSCLC tumors that progress after EGFR-TKI treatment (67).